Ownership signal CIK-linked ownership evidence from parsed SEC filings. 2 signals
Large-stake signal

Form

SCHEDULE 13G/A

Passive or exempt beneficial ownership filing.

Ownership

14%

Beneficial ownership of this reported class.

Shares

3,247,162 shares

Shares beneficially owned as disclosed.

Event date

31 Mar 2026

Date tied to the ownership event or amendment.

Accepted by SEC

15 May 2026

EDGAR acceptance date.

How to read this large-stake filing
  • Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
  • Compare this filing with the holder history and issuer page before treating the percentage as a current position.
  • Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
Subject security Names, identifiers, and filing context for this profile. 2 source fields
Symbol
LYEL
Shares outstanding
23,360,878 shares
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
SCHEDULE 13G/A
Accepted by SEC
15 May 2026, 16:05:03 UTC
Event date
31 Mar 2026
Prior SEC filing
14 Feb 2025
Source filing
View source filing

Key filing fact

ARCH Venture Fund IX, L.P. disclosed 14% ownership in Lyell Immunopharma, Inc. Common Stock par value $0.0001 per share (LYEL) on 31 Mar 2026.

Key facts

  • ARCH Venture Fund IX, L.P. filed SCHEDULE 13G/A for Lyell Immunopharma, Inc. Common Stock par value $0.0001 per share (LYEL).
  • Disclosed ownership: 14%.
  • Date of event: 31 Mar 2026.

Change

  • Previous schedule filing date: 14 Feb 2025.
  • Current filing was accepted on 15 May 2026, 16:05.

Research use

  • This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
  • Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

View source filing

Reporting persons

Disclosed reporting parties (14)

Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares owned Sole voting power Shared voting power Signature Title CIK
ARCH Venture Fund IX, L.P. 14% 3,247,162 0 3,247,162 /s/ ARCH Venture Partners IX, L.P. its General Partner
ARCH Venture Fund IX Overage, L.P. 14% 3,247,162 0 3,247,162 /s/ ARCH Venture Partners IX Overage, L.P. its General Partner
ARCH Venture Fund XIII, L.P. 14% 3,247,162 0 3,247,162 /s/ ARCH Venture Partners XIII, L.P. its General Partner
ARCH Venture Partners IX, L.P. 14% 3,247,162 0 3,247,162 /s/ ARCH Venture Partners IX, LLC its General Partner
ARCH Venture Partners IX Overage, L.P. 14% 3,247,162 0 3,247,162 /s/ ARCH Venture Partners IX, LLC its General Partner
ARCH Venture Partners IX, LLC 14% 3,247,162 0 3,247,162 /s/ Mark McDonnell Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
ARCH Venture Partners XIII, L.P. 14% 3,247,162 0 3,247,162 /s/ ARCH Venture Partners XIII, LLC its General Partner
ARCH Venture Partners XIII, LLC 14% 3,247,162 0 3,247,162 /s/ Mark McDonnell Mark McDonnell as Attorney-in-Fact for Keith Crandell, Managing Director
Keith Crandell 14% 3,247,162 0 3,247,162 /s/ Mark McDonnell Mark McDonnell as Attorney-in-Fact for Keith Crandell
Clinton Bybee 7.8% 1,820,634 0 1,820,634 /s/ Mark McDonnell Mark McDonnell as Attorney-in-Fact for Clinton Bybee
Robert Nelsen 14% 3,247,162 0 3,247,162 /s/ Mark McDonnell Mark McDonnell as Attorney-in-Fact for mark McDonnell
Kristina Burow 14% 3,247,162 0 3,247,162 /s/ Mark McDonnell Mark McDonnell as Attorney-in-Fact for Kristina Burrow
Steven Gillis 14% 3,247,162 0 3,247,162 /s/ Mark McDonnell Mark McDonnell as Attorney-in-Fact for Steven Gillis
Paul Berns 6.1% 1,426,528 0 1,426,528 /s/ Mark McDonnell Mark McDonnell as Attorney-in-Fact for Paul Berns
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .